Cipla has completed acquisition and subscription of additional shares in GoApptiv, associate company. Accordingly, Cipla will now hold 22.99% stake on a fully diluted basis in GoApptiv. This is Cipla’s third investment in GoApptiv, which will be made in a combination of equity shares and compulsorily convertible preference shares. GoApptiv has experienced significant expansion in underpenetrated areas and product lines following prior investments by Cipla in 2022 and 2020.
In line with Cipla’s ambition to strengthen investments in channels of the future, this development will further expand Cipla’s presence across the healthcare continuum, especially to the underserved population by enabling greater access to lifesaving treatments.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1519.75 |
Dr. Reddys Lab | 6287.70 |
Cipla | 1411.30 |
Zydus Lifesciences | 963.40 |
Lupin | 1653.55 |
View more.. |